Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Medical Access Program for Valemetostat Tosylate (DS 3201b) For The Treatment of Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL) Originating From Mature T Cells (Including But Not Limited to Adult T-cell Leukemia/Lymphoma [ATLL], Anaplastic Large Cell Lymphoma [ALCL], Refractory Nodal T-Follicular Helper Lymphoma [nTFHL]), Regardless of CD30 Who Have Failed on 2 or More Lines of Treatments

NCT07862465 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT07862465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07862465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Medical Access Program for Valemetostat Tosylate (DS 3201b) For The Treatment of Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL) Originating From Mature T Cells (Including But Not Limited to Adult T-cell Leukemia/Lymphoma [ATLL], Anaplastic Large Cell Lymphoma [ALCL], Refractory Nodal T-Follicular Helper Lymphoma [nTFHL]), Regardless of CD30 Who Have Failed on 2 or More Lines of Treatments
Lead sponsor
Daiichi Sankyo
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

adult t-cell leukemia/lymphoma, anaplastic large cell lymphoma, peripheral t-cell lymphomas, refractory nodal t-follicular helper lymphoma